The Bifidobacterium lactis LAFTI B94 was identified as having strong probiotic potential during the 8 years of Co-operative Research Centre for Food Industry Innovation research at the University of New South Wales in collaboration with CSIRO Division of Dairy Research. Several studies have since been conducted on the beneficial effects of this particular strain at effectively suppressing bad bacteria, copies of which can be found at the following links:
Beneficial effects of B94 on premature babies in reducing Necrotising Enterocolitis - Necrotising Entercolitis (NEC) is essentially the gut of pre-term babies dying from the inside out due to what is most likely infection with particularly bad strains of proteolytic bacteria (protein eating bacteria). Although this study is focussed on premature babies, it has implications for other similar gut disorders in adults.
Treatment Outcomes of Infants With Cyanotic Congenital Heart Disease Treated With Synbiotics - similar to the above link, this study was done in pre-term babies, but this study focussed on the link between NEC, congenital heart disease, and improved survivability when the B94 strain was used on premature babies.
The Comparition of the Efficacy of Two Different Probiotics in Rotavirus Gastroenteritis in Children - This study looked at how the B94 strain impacted on the severity and duration of gastro symptoms, specifically gastro caused by Rotavirus infection.
The role of Bifidobacterium lactis B94 plus inulin in the treatment of acute infectious diarrhea in children - another gastro study, this time not specific to Rotavirus infection.